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ORIGINAL ARTICLE
Prevalence of iron deficiency anemia and iron deficiency in a pediatric
population with inflammatory bowel disease
Fabia Susana Ginja de Carvalho, Inês Ambrosio de Medeiros and Henedina Antunes
Gastroenterology, Hepatology and Nutrition Unit, Pediatrics Department, Hospital de Braga, Braga, Portugal
ABSTRACT
Objectives: Iron deficiency is the most common cause of anemia in children with inflammatory bowel
disease, although the real prevalence is unknown. Intravenous iron is suggested as the first line treat-
ment. This study aims to determine the prevalence of iron deficiency anemia in children with inflam-
matory bowel disease followed in a Pediatric Gastroenterology Unit of a tertiary center and to evaluate
this unit's experience with intravenous iron.
Materials and methods: A retrospective cohort study was designed involving children with inflamma-
tory bowel disease followed in that unit between January 2001 and April 2016. Laboratory results were
collected at the moment of diagnosis, after one-year follow-up and prior each IV iron administration
performed during the study period. Anemia was defined according to World Health Organization crite-
ria and the iron deficiency was defined using recent guidelines.
Results: Were studied 69 patients 71% had CD and 29% UC. 50.7% were female. Mean patient age at
diagnosis was 13.3 years (range 1–17 years). Prevalence of ID and IDA at diagnosis was 76.8% and
43.5%, respectively. After one year follow-up, those values decreased to 68.1% (p¼ .182) and 21.7%
(p¼ .002), respectively. Hemoglobin significantly increased (p< .001). Intravenous iron was administered
to 92.8% of patients. No adverse reactions were reported.
Conclusions: Intravenous iron is the first line in the treatment of Iron deficiency anemia in
Inflammatory Bowel disease and it is safe and effective. Persistent anemia and iron deficiency are
common.
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Anemia is the most common systemic complication of
inflammatory bowel disease (IBD) [1]. The etiology is multi-
factorial, but in 80% of cases it results due to the combin-
ation of iron deficiency anemia (IDA) and anemia of chronic
disease (ACD) [2–4]. The true prevalence of iron deficiency
(ID) and IDA in the pediatric population is unknown. In
recent studies, Goodhand et al. and later Danko estimated it
to be up to 70% at diagnosis and even after two years of fol-
low-up prevalence can be as high as 30% [2,4–10].
ID has an adverse impact on quality of life [6,9,11,12].
Therefore, it is important to carefully evaluate iron status of
all patients so that ID and IDA can be diagnosed and treated
timely [7,8].
Studies on ID and IDA in children are scarce and difficult
to compare because most times different cut-off values are
used to define anemia and the interpretation of iron indices
must take into account inflammation parameters. In context
of IBD, interpreting serum ferritin relative to C-reactive pro-
tein has been proposed as a method to detect iron defi-
ciency [2,8,9].
Oral iron was once the standard treatment of IDA and ID.
Recently, its gastrointestinal side-effects, slow onset of action
and negative impact on disease activity gave rise to the use
of intravenous formulations [2,5,6,9,13–15]. There have been
some concerns regarding the safety of these preparations in
the pediatric population, mainly with dextran formulations
which carry increased risk of anaphylaxis [6,8,9,15,16]. But,
now, the new formulas such as iron sucrose and ferric car-
boxymaltose (FCM), the last one still only approved for
patients over 14 years, have better safety profiles and are
now the first line treatment for IDA and ID in IBD patients
[3,4,8,9,16–18].
There are few studies that estimate the prevalence of ID
and IDA in pediatric IBD patients and even fewer that evalu-
ate the efficacy of intravenous iron to treat them [1,4,5].
Thus, the aim of this study was to calculate the prevalence
of ID and IDA in children with IBD followed in a Pediatric
Gastroenterology Unit and evaluate this unit’s experience in
their treatment with IV iron.
Materials and methods
Study sample, design and approval
A retrospective cohort study was conducted in the
Gastroenterology, Hepatology and Nutrition Unit of the
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Pediatrics Department of Hospital de Braga, a tertiary unit
that serves the region of Minho. The primary objective of this
study was to evaluate the changes in ID and IDA’s prevalence
after the first-year of diagnosis. In order to do that, we deter-
mine the prevalence of ID and IDA at the moment of diagno-
sis and after the first-year of follow-up. A secondary objective
of this study was to evaluate this unit’s experience with intra-
venous iron therapy in the last 15 years.
All pediatric patients (under 18 years) diagnosed with IBD
and followed in that unit between January 2001 and April
2016 were selected and their electronic health record
reviewed. Patients with an incomplete electronic health
record, who have not completed one-year follow-up, with
hemoglobinopathies and history of previous blood transfu-
sions were excluded. All data collected, as well as the study
design, were approved by the institutional review board and
ethics committee. Patient identities were protected during
the study.
Study variables
All data were collected from the electronic health record and
included demographic information (actual age, gender, age
at diagnosis), medical history and status of patient’s IBD at
diagnosis. Prevalence of ID and IDA was obtained by study-
ing hemoglobin (Hb), C-reactive protein (CRP) and ferritin val-
ues at diagnosis and after one-year follow-up. To evaluate
the unit’s experience with IV iron therapy, all IV iron adminis-
trations that took place in that unit during the 15 years
studied were analyzed. Laboratory values prior to each IV
iron administration, such as Hb, CRP, ferritin, mean corpuscu-
lar volume (MCV) and hematocrit (Ht) were analyzed, and all
adverse reactions and the iron cumulative dose administered
to each patient during their first year follow-up and during
their entire follow-up in the Unit were registered.
Definitions of Disease Activity, Anemia and Iron
Deficiency
Anemia was defined according to World Health Organization
cut-offs for Hb concentration specific to age groups and gen-
der: under 5 years, anemia was defined as Hb concentration
under 110g/L, between 5 and 11 years Hb under 115g/L,
between 12 and 14 years under 120g/L, non-pregnant girls
over 15 years under 120g/L and boys over 13 years under
130g/L. ID was defined as serum ferritin < 30lg/L when CRP
< 10mg/L and serum ferritin <100 lg/L when there was evi-
dence of inflammation (CRP >10mg/L). In our group, we
elected these criteria since it takes into account the fact that
ferritin can be altered by inflammation itself.
Disease activity was defined according to PCDAI index
and CRP values in Crohn’s disease (CD) and PUCAI index and
clinical features were used to divide Ulcerative Colitis (UC)
patients in mild, moderate and severe.
Intravenous iron treatment
IV iron was used as the first line in treatment of ID and IDA;
oral iron was prescribed only when the patient refused IV
administration. The IV iron deficit was calculated according
to the Ganzoni formula [Weight (kg) (target Hb- real Hb g/
dlx0.24)þ iron stores (>35 kg: 500mg, < 35 kg: 15mg/kg)]
[19]. The maximum single dose allowed per infusion was
200mg per day. When deficit was superior, the patient was
submitted to several infusions in consecutive days. After the
successful treatment of IDA or ID with IV iron, it was reiniti-
ated as soon as the serum ferritin level dropped, which was
determined every three to six months according to disease’s
activity. The variable ‘treatment’ was defined as the total
number of infusions needed to treat or prevent ferropenia.
All patients submitted to IV iron therapy received iron
sucrose. Adverse side effects were considered within the first
24h after iron administration.
Statistical analysis
Statistical analysis was performed using SPSSVR 21.0 (Chicago,
IL). Laboratory values were expressed as mean. Changes in
CRP, ferritin, Hb values and in the prevalence of anemia, IDA
and ID from diagnosis to one-year follow-up were evaluated
using a paired t-test. All p-values are 2-sided and p< .05 was
used to define statistical significance.
Pearson’s correlation was used to determine associations
between disease severity and Hb values and between disease
severity and cumulative iron dose. Correlation between age
at diagnosis and the cumulative iron dose was also studied
using a level of significance of .01.
Results
During the study period, 100 patients were diagnosed with
IBD, 16 were excluded because their electronic health record
was incomplete and 15 were excluded because they have
not completed one-year follow-up. From the remaining 69
patients included in the study, 71% (49) had CD and 29%
(20) UC. 50.7% were female. Mean patient age at diagnosis
was 13.3 years (range 1–17 years) with no statistical differ-
ence between both the groups (DC and UC – p¼ .937).
Prevalence of ID and IDA at diagnosis was 76.8% and
43.5%, respectively. After one year follow-up, ID decreased to
68.1% (p¼ .182) and IDA to 21.7% (p¼ .002). At diagnosis, 12
patients presented with severe anemia, after one year four
patients still presented Hb levels under 100g/L (Table 1).
Mean hemoglobin levels were significantly higher after
one-year follow-up (mean Hb levels at diagnosis: 117g/L and
after one-year follow-up: 128g/L – p¼ .0001) and mean CRP
values were significantly lower (at diagnosis 29.78mg/L and
after one year 7.87mg/L – p< .001). There were no significant
changes in mean ferritin levels (52.29ng/mL at diagnosis and
42.47ng/mL after one-year follow-up p¼ .146).
Table 1. Prevalence of anemia, severe anemia, iron deficiency and iron defi-
ciency anemia at diagnosis and after one year follow-up.
At diagnosis After 1 year follow-up p Value
Anemia 36/69 (43.5%) 17/69 (24.6%) .0001
Anemia Hb <100g/L 12/69 (17.4%) 4/69 (5.8%) .020
Iron Deficiency 53/69 (76.8%) 47/69 (68.1%) .182
Iron Deficiency Anemia 30/69 (43.5%) 15/69 (21.7%) .002
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At diagnosis, mean Hb levels were significantly higher for
CD patients (p¼ .009) but, after one-year follow-up, were
similar for both pathologies (p¼ .901). After one-year follow-
up, mean CRP values decreased below 10mg/L for both
groups but were higher for patients with CD (p¼ .005). CD
patients presented superior ferritin values (p¼ .0001 and
p¼ .010). IV iron was administered to 92.8% (n ¼ 64) of
patients. Ten patients started treatment with oral iron but
interrupted it because of gastrointestinal intolerance. IV
administration was equally preferred in both pathologies
(p< .001 and p< .001).
During 15 years, 441 infusions of IV iron were conducted
in that Unit, with a mean cumulative dose per patient of
832.95mg and a mean dose per weight of 2.26mg/kg.
During the entire follow-up period, each patient received a
mean of eight treatments. Considering the total number of
infusions occurred in that unit, about 50% were performed
during patient’s first year of follow-up. On average, each
patient received from 2 to 10 infusions per treatment to pre-
vent iron deficit or to restore total deficit. Overall cumulative
dose during the first year was superior for UC patients
(875mg vs 452.94mg – p¼ .008), however, during the entire
study period, cumulative dose was similar for both UC and
CD patients (989.47mg vs 762.14 – p¼ .219). No adverse
reactions were reported. There were no clinical infections fol-
lowing IV iron treatment. Median time between diagnosis
and first infusion of IV iron was higher for UC patients (2
(min 0; max 72) months vs 7 (min 0; max 65) months –
p¼ .277). Analyzing all IV iron administrations, we found that
severe disease was associated with lower Hb levels at diag-
nosis (r¼ 0.139 significant correlation for significance level
.01) and higher cumulative iron sucrose doses over the
course of the study (r¼ .267 significant correlation for signifi-
cance level .05).
Crohn’s disease
Changes in prevalence of ID, IDA and anemia in CD are sum-
marized in Table 2.
During study period, 49 patients were diagnosed with
CD, 46.9% feminine and 53.1% masculine; mean age 13.29
years (range 1–17 years). At the moment of diagnosis, dis-
ease activity was classified as ‘moderate’ in 79.6% of
patients and as ‘severe’ in 16.4%, according to PCDAI and
CRP values.
In CD patients mean hemoglobin concentration at diagno-
sis was 121g/L (85–165g/L) and after one-year follow-up,
there was a significant increase to 129g/L (81–168g/L) –
p¼ .0001. The proportion of patients with Hb < 100g/L
decreased from 10.2% to 4.08% (p¼ .034). There was a
significant decrease in CRP values (from 27.46 to 9.93mg/L –
p¼ .0001), reflecting a good control of the disease after one-
year follow-up. Ferritin showed no significant alteration after
one year (65.16ng/mL at diagnosis and 49.15ng/mL after
one-year follow-up – p¼ .068).
Mean cumulative dose of IV iron received during study
period was 762.14mg (min 100mg; max 3300mg); during the
first year 60% of that dose was administered (452.94mg –
min 100mg; max 2300mg); mean dose of iron sucrose per
weight received in one day was similar in both periods
(2.31mg/kg vs 2.36mg/kg – min 1.23mg/kg; max 11.36mg/
kg). On average, each CD patient needed two to four IV iron
infusions per treatment. Mean time since diagnosis until the
first IV iron administration was 2 months (min 0; max
72 months).
Ulcerative colitis
Changes in prevalence of ID, IDA and anemia in UC are sum-
marized in Table 3. During the study period, 20 patients
were diagnosed with UC, 60% feminine and 40% masculine;
mean age 13.35 years (range 5–17 years). At the moment of
diagnosis, disease activity was classified as ‘moderate’ in 50%
of patients and as ‘severe’ in 35%, according to PUCAI values
and clinical features.
In UC patients, mean hemoglobin concentration at diag-
nosis was 107g/L (50–146g/L) and after one-year follow-up
there was a significant increase to 128g/L (82–156g/L) –
p¼ .009. The proportion of patients with Hb <100g/L
decreased from 30% to 10% (p¼ .026). There was a
significant decrease in CRP values (from 35.45 to 2.82mg/L –
p¼ .005) reflecting a good control of the disease after one-
year follow-up. Ferritin showed no significant alteration
after one year (20.75ng/mL at diagnosis and 26.1ng/mL after
one-year follow-up – p¼ .555).
Mean cumulative dose of IV iron received during study
period was 989.47mg (min 100mg; max 2800mg); during the
first year was administered 88% of total dosage (875mg –
min 100mg; max 1500mg), mean dose of iron sucrose per
weight received in one day was higher in the first year
(2.9mg/kg vs 2.5mg/kg – min 1.25mg/kg; max 11.9mg/kg).
On average, each UC patient received 2–10 infusions per
treatment. Mean time since diagnosis until the first IV iron
administration was 7 months (min 0; max 65 months).
Discussion
To our knowledge, there are few studies that report the
prevalence of IDA and ID in the pediatric population with
IBD. The results obtained are in accordance with previous
Table 2. Prevalence of anemia, severe anemia, iron deficiency and iron defi-
ciency anemia at diagnose and after one year follow-up in Crohn’s disease
patients.
At diagnose After 1 year follow-up p Value
Anemia 23/49 (46.9%) 11/49 (22.4%) .0001
Anemia Hb <100g/L 6/49 (12.2%) 2/49 (4.01%) .034
Iron Deficiency 34/49 (69.4%) 31/49 (63.3%) .473
Iron Deficiency Anemia 17/49 (34.7%) 10/49 (20.4%) .051
Table 3. Prevalence of anemia, severe anemia, iron deficiency and iron defi-
ciency anemia at diagnose and after one year follow-up in Ulcerative Colitis
patients.
At diagnose After 1 year follow-up p Value
Anemia 13/20 (65%) 6/20 (30%) .031
Anemia Hb <100g/L 6/20 (30%) 2/20 (10%) .026
Iron Deficiency 19/20 (95%) 16/20 (80%) .083
Iron Deficiency Anemia 13/20 (65%) 5/20 (25%) .017
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studies revealing that the prevalence of ID was higher than
IDA’s [1,2,20]. We concluded that iron sucrose treatment sig-
nificantly decreased the prevalence of IDA after one-year fol-
low-up. In fact, more than 50% of the iron cumulative dose
was administered during the first year.
Globally we achieved a good disease control in our
patients after one year, as the mean CRP values significantly
decreased under 10mg/L for both pathologies. Therefore, we
hypothesize that the non-significant decrease in ID and the
persistence of anemia was a consequence of some patients
requiring more iron to restore their reserves as well as other
confounding factors such as anemia of chronic diseases.
In fact, one cannot forget that IBD pathophysiology itself
gives patients a predisposition to an imbalance in iron’s
metabolism. Indeed, these patients not only tend to have a
diet poor in many nutrients, including iron but also, present
impaired absorption and increased intestinal blood loss,
especially those with UC. All of these associated with
increased requirements during growth explains a tendency
to iron deficiency [2,8,11,21]. Also we believe that in some
cases IDA/ID could be underdiagnosed.
UC group presented a higher prevalence of anemia and
severe anemia. That can be explained because those patients
tend to lose more blood when disease relapses [1,17].
Recently published ECCO guidelines [17] consider intravenous
iron as the first line option in ID/IDA treatment and recom-
mend that IV iron therapy should be initiated as soon as the
serum ferritin levels started to drop. Our unit’s protocol for
the treatment of ID and IDA follows those guidelines and the
authors consider that aggressive treatment and screening of
ID/IDA has a major influency on disease control; we consider
WHO definition of anemia and define ID and IDA according
to disease activity index (PUCAI and PCDAI) and values of
serum ferritin and CRP (serum ferritin < 30lg/L when CRP
< 10mg/L and serum ferritin < 100 lg/L when CRP >10mg/
L). We apply the same guidelines to UC and CD patients. Our
results, despite having some limitations, support previous
studies, proving that IV iron therapy is safe, feasible and
effective using the lowest recommended safe dose (3mg/
kg, maximum 200mg/infusion) [2,6,8,9,15].
We have not reported any side effects associated with IV
iron therapy. On the other hand, patients who tried oral iron
therapy had to interrupt it because of gastrointestinal intoler-
ance, non-adherence or bad response. From our experience
with IV iron therapy, we reinforce its safety profile, largely
studied in the adult population, since no adverse effects
were observed. Once more it is proven that IV iron therapy is
able to bypass gastrointestinal intolerance of oral iron while
allowing for higher single doses to be administered in
shorter periods of time [2,9,15,17,22]. With this study, we
hope to provide a significant impact on quality of life and
disease control of patients by treating ID and IDA.
Furthermore, as it was reported before by Danko et al. in
2016, for patients requiring periodic IV access it wasn't diffi-
cult to incorporate IV iron treatment in their routine, and we
notice that it was better tolerated than adding another oral
medication [6,15].
In our hospital we have only recently started to have
access to FCM, so all of these administrations refer to iron
sucrose. In our study, we reported mean cumulative doses of
832mg that sometimes required 5 administrations. While,
Laass et al. [8], and later Azevedo et al. [9], reported mean
cumulative doses of FCM of 821mg and 811.5mg, respect-
ively, administered in 2 and 1 administrations. This is consist-
ent with previous reports that indicate that iron sucrose
requires more infusions and higher doses to replace total
deficit.
There are few studies in pediatric patients using FCM. This
formulation has the advantage to permit higher single doses
of iron to be administered in shorter periods of time with
less overall infusions improving the quality of life and
resource saving [8]. Azevedo et al. in 2016 have proven that
FCM is equally effective as iron sucrose and achieved higher
mean Hb levels. [9] They reported mean Hb values of 131g/L
in FCM-treated patients group compared to our mean Hb
levels of 128g/L that were similar to those in their group
treated with iron sucrose.
We recognize that the retrospective nature of this study
may introduce bias. For example, the lack of a comparison
with oral therapy and blood results six weeks after IV iron
infusion inhibits the correct evaluation of iron therapy effi-
cacy. In fact, with this study, we can only imply indirectly its
efficacy by evaluating changes in Hb values and ID/IDA
prevalence after one-year follow-up. Also, due to the obser-
vational nature of this study, we cannot confirm that the
patient recovery from ID/IDA is only related to iron supple-
mentation, other variables should be studied. We believe
that we tend to select the most critical patients since those
are more likely to have frequent blood analysis (besides the
regular analytic control from 3 to 3 months), thus we might
be underdiagnosing ID and IDA in milder patients.
Overall, despite further randomized controlled studies
being needed on this matter, the authors recommend the
use of IV iron as the first line in the treatment of IDA and ID
in IBD pediatric patients. Reliable diagnostic criteria to timely
identify ID and IDA are valuable since a prompt intervention
has a significant impact on quality of life and disease control.
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